Similar observations were found in lung adenocarcinoma, patients with hypomethylation in PSMB8 promoter region exhibited greater activation of immune-related pathways, increased numbers of antitumor immune cells, and longer PFI following PD1/PDL1 treatment compared to those with hypermethylation in PSMB8 promoter region [30]. The gene discussed is PSMB8; the disease is lung adenocarcinoma.